9 / 16
Page 22
Notes:
allied
academies
July 23-25, 2018 | Moscow, Russia
12
th
World Cancer Congress
Journal of Medical Oncology and Therapeutics | Volume: 3
U
ntil a few decades ago, peritoneal dissemination of
gastrointestinal cancer was regarded as a sign of systemic
disease unsuitable for surgical treatment and was treated with
palliative chemotherapy only.
In the 1980s, the association between hyperthermia and
chemotherapy generated considerable interest as studies in
vitro showed that hyperthermia did indeed potentiate the
effects of antiblastic drugs. After this time two new surgical
technologies that have evolved to manage peritoneal
metastases are cytoreductive surgery (CRS) and hyperthermic
intraperitoneal chemotherapy (HIPEC). This combined
treatment strategy uses peritonectomy procedures and
visceral resections to reduce the disease in the abdomen
and pelvis to a macroscopic volume. Then, HIPEC is used
to preserve the complete cytoreduction by controlling the
minimal residual disease.
With the progression of surgical technologies and
techniques, the morbidity and mortality of such treatment
approaches have also decreased accordingly with a
corresponding increase in the overall survival. Long-term
median survival of 34 - 92 months and 5 year survival of
29 - 59 % can be expected from selected group of patient..
Speaker Biography
Taylan Ozgur Sezer is a Associate Professor of General Surgery, Head of the Periton
Malignancy and Renal Transplantation. Specialist in periton malignancy, Medicine
Doctor’s degree at Ege University School of Medicine. Currently his researches
focus on the effects of hyperthermia on cancer cell DNA and cancer vaccine.
e:
taylan.ozgur.sezer@ege.edu.trTaylan Ozgur Sezer
Ege University Hospital, Turkey
Timing and role of Hypertermic Chemotherapy in peritoneal metastases of
Gastrointestinal Cancers